Document:

Exhibit 10.43

 

THIS AMENDMENT (this “Amendment”)
TO TRANSACTION AGREEMENT dated as of October 4, 2021 (as amended hereby, the “Transaction Agreement”; and all defined
terms used herein that are not otherwise defined are used as defined in the Transaction Agreement) by and between AiPharma Global Holdings
LLC, a Delaware limited liability company (“AiPharma”), and Aditxt, Inc., a Delaware corporation (“Aditxt”,
and together with AiPharma, the “Parties” and each, a “Party”) is dated as of November 30, 2021.

 

WHEREAS, the Parties have agreed to the terms set
forth in this Amendment.

 

NOW, THEREFORE, the Parties agree as follows.

 

Article 1. Amendments.

 

Section 1.1 Section 1(a) of the Transaction Agreement is hereby
amended to replace “$8,500,000” in the first sentence with “$8,000,000,” and the term “Borrowing Capacity”
shall mean “$8,000,000.”

 

 Section 1.2  Section 4(b) of the Transaction Agreement is hereby
amended to delete the words “and paying the fee required by Section 11(e)” at the end of the proviso.

 

 Section 1.3  Section 11(a)(ii) of the Transaction Agreement
is hereby amended to redefine the term “Outside Date” as December 10, 2021.

 

 Section 1.4 Section 11(b) of the Transaction Agreement is hereby
amended and restated in its entirety to read as follows:” If this Agreement is terminated by either Party pursuant to Section 11(a),
then this Agreement shall become void and of no effect without liability of any party (or any representative of such party) to any other
party hereunder; provided, that the obligations under the Loan Documents shall survive any termination of this Agreement.”

 

 Section 1.5 Section 11(c) through Section 11(f) and Section
11(i) are hereby deleted in their entirety and replaced with “[Intentionally omitted]”.

 

Section 1.6 Section 11(g) of the Transaction
Agreement is hereby amended and restated in its entirety to read as follows: “The obligation of AiPharma to make the $4M payment
contemplated by the Loan Documents (the “$4M Payment”) is hereby terminated and with no further force or effect.” 

 

    -1- 

     

    

 

Article 2. Miscellaneous.

 

Section 2.1 No Amendments.
Except as previously amended in writing or as amended hereby, the Transaction Agreement shall remain unchanged and all provisions shall
remain fully effective between the parties.

 

 Section 2.2 Severability. Any provision of this Amendment
held by a court of competent jurisdiction to be invalid or unenforceable shall not impair or invalidate the remainder of this Amendment
and the effect thereof shall be confined to the provision so held to be invalid or unenforceable.

 

 Section 2.3 Ratifications. The terms and provisions set
forth in this Amendment shall modify and supersede all inconsistent terms and provisions set forth in the Transaction Agreement and, except
as expressly modified and superseded by this Amendment, the terms and provisions of the Transaction Agreement are ratified and confirmed
and shall continue in full force and effect. The Parties agree that the Transaction Agreement shall continue to be legal, valid, binding
and enforceable in accordance with its terms.

 

 Section 2.4 Counterparts. This Amendment may be executed
in any number of counterparts, each of which when executed and delivered shall be deemed an original, but all of which constitute one
instrument. In making proof of this Amendment, it shall not be necessary to produce or account for more than one counterpart thereof signed
by each of the Parties. Signatures transmitted by facsimile, electronic mail or other electronic transmission shall be effective as originals.

 

    -2- 

     

    

 

IN WITNESS WHEREOF, the undersigned have executed this Amendment as
of the date first set forth above.

 

	Aditxt, Inc.	 	AiPharma Global Holdings LLC
	 	 	 	 	 	 	 
	By:	/s/ Amro Albanna	 	By:	/s/ Alessandro Gadotti
	 	Name: 	Amro Albanna	 		Name: 	Alessandro Gadotti
	 	Title:	CEO	 	 	Title:	CEO

 

 

-3-Exhibit 10.44

 

THIRD AMENDMENT TO SECURED
CREDIT AGREEMENT

 

THIRD AMENDMENT TO SECURED CREDIT AGREEMENT dated
as of November 30, 2021 (this “Amendment”), between AiPharma Global Holdings
LLC, a Delaware limited liability company (“DE Topco”), AIPHARMA HOLDINGS LIMITED, a company formed under the
laws of the British Virgin Islands (“BVI Holdco”) and AIPHARMA ASIA LIMITED, a company formed under the laws of Hong
Kong (“HK Opco” and together with DE Topco and BVI Holdco, individually and collectively, the “Borrower”)
and Aditxt, Inc., a Delaware corporation (the “Lender”).

 

RECITALS

 

A.
Lender made a loan to Borrower pursuant to a Secured Credit Agreement, dated as of August 27, 2021 (as the same may be amended, supplemented
or otherwise modified from time to time, the “Credit Agreement”).

 

B.  Lender
and Borrower desire to amend the Credit Agreement on the terms set forth herein.

 

In consideration of the mutual covenants and agreements
herein contained and contained in the Transaction Agreement, the parties hereto agree as follows:

 

	1.	Defined Terms. Any and all initially capitalized terms used in this Amendment (including, without limitation, in the Recitals
to this Amendment) without definition shall have the respective meanings assigned thereto in the Credit Agreement, or if not defined therein,
as defined in the Transaction Agreement.

 

	2.	Amended Defined Terms. The following defined terms, as set forth in Section 1.01 of the Credit Agreement, are hereby
amended and restated in their entirety to read as follows:

 

“Borrowing Capacity”
means $8,000,000.

 

“Maturity Date” means
December 10, 2021.

 

	3.	Credit Extensions. Section 2.05 of the Credit Agreement is hereby amended to read in full as follows:

 

SECTION 2.05 [Intentionally Omitted]

 

	4.	Miscellaneous Provisions. The provisions of Article VIII of the Credit Agreement are incorporated herein by this reference
mutatis mutandis.

 

[Signature page follows]

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Amendment to be duly executed by their respective authorized officers as of the day and year first above written.

 

	 	AIPHARMA GLOBAL HOLDINGS LLC,
	 	a Delaware limited liability company
	 	 	 
	 	By: 	/s/ Alessandro Gadotti
	 	 	Name:	Alessandro Gadotti
	 	 	Title:	CEO
	 	 	 
	 	AIPHARMA HOLDINGS LIMITED,
	 	a company formed under the laws of the British Virgin Islands
	 	 	 
	 	By: 	/s/ Alessandro Gadotti
	 	 	Name: 	Alessandro Gadotti
	 	 	Title: 	CEO
	 	 	 
	 	AIPHARMA ASIA LIMITED,
	 	a company formed under the laws of Hong Kong
	 	 	 
	 	By: 	/s/ Alessandro Gadotti
	 	 	Name: 	Alessandro Gadotti
	 	 	Title: 	Legal representative / CEO
	 	 	 
	 	ADITXT, INC., a Delaware corporation
	 	 	 
	 	By: 	/s/ Amro Albanna
	 	 	Name: 	Amro Albanna
	 	 	Title: 	 

 

Borrowing RequestExhibit 10.45

 

THIS SECOND AMENDMENT, dated as of December 7, 2021 (this “Amendment”),
to that certain Transaction Agreement dated as of October 4, 2021 (as amended hereby and by the First Amendment dated as of December 1,
2021, , the “Transaction Agreement”; and all defined terms used herein that are not otherwise defined are used as defined
in the Transaction Agreement), is entered into by and between AiPharma Global Holdings LLC, a Delaware limited liability company (“AiPharma”),
and Aditxt, Inc., a Delaware corporation (“Aditxt”, and together with AiPharma, the “Parties” and
each, a “Party”).

 

WHEREAS, the Parties desire to further amend the
Transaction Agreement as set forth herein.

 

NOW, THEREFORE, in consideration for the promises
contained herein and the mutual obligations of the Parties, the receipt and sufficiency of which are hereby expressly acknowledged, the
Parties, intending to be legally bound, hereby agree as follows:

 

Article 1. Amendments.

 

 Section 1.1 Section 4(b) of the Transaction Agreement is hereby
amended by deleting this provision in its entirety and replacing it with “[Intentionally omitted]”.

 

 Section 1.2  Section 4(c)(ii) of the Transaction
Agreement is hereby amended by deleting the provision in its entirety and replacing it with “[Intentionally omitted]”.

 

 Section 1.3  Section 4(d) of the Transaction Agreement is hereby
amended by deleting the provision in its entirety and replaced with “shall
be permitted, and its subsidiaries shall be permitted, to issue equity interests (including rights to acquire equity interests) of such
Party and such subsidiaries as it determines after consultation with the other Party.”

 

 Section 1.4  Sections 11(a)(vi) and 11(a)(vii)
of the Transaction Agreement are hereby deleted in its entirety.

 

Section 1.5. AiPharma hereby
waives compliance with the Transaction Agreement with respect to Aditxt’s entry into that certain Letter of Intent with xxx dated
December 1, 2021 and hereby consents to Aditxt’s entry into this agreement.

 

    -1-

     

    

 

Article 2. Miscellaneous.

 

 Section 2.1 Severability. Any provision of this Amendment
held by a court of competent jurisdiction to be invalid or unenforceable shall not impair or invalidate the remainder of this Amendment
and the effect thereof shall be confined to the provision so held to be invalid or unenforceable.

 

 Section 2.2 Ratifications. The terms and provisions set
forth in this Amendment shall modify and supersede all inconsistent terms and provisions set forth in the Transaction Agreement and, except
as expressly modified and superseded by this Amendment, the terms and provisions of the Transaction Agreement are ratified and confirmed
and shall continue in full force and effect. The Parties agree that the Transaction Agreement shall continue to be legal, valid, binding
and enforceable in accordance with its terms.

 

 Section 2.3 Counterparts. This Amendment may be executed
in any number of counterparts, each of which when executed and delivered shall be deemed an original, but all of which constitute one
instrument. In making proof of this Amendment, it shall not be necessary to produce or account for more than one counterpart thereof signed
by each of the Parties. Signatures transmitted by facsimile, electronic mail or other electronic transmission shall be effective as originals.

 

 Section 2.4 Entire Agreement. This Amendment and the
Transaction Agreement constitute the entire agreement among the Parties with respect to the subject matter hereof and thereof, and supersede
all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.

 

 Section 2.5 Miscellaneous. The terms and provisions of
Sections 6, 7, 8, 9, 13, 14 and 15 of the Transaction Agreement are incorporated herein by reference as if set forth herein and shall
apply mutatis mutandis to this Amendment.

 

    -2-

     

    

 

IN WITNESS WHEREOF, the undersigned have executed
this Amendment as of the date first set forth above.

 

	AiPharma Global Holdings LLC	 
	 	 	 	 
	By:	/s/ Alessandro Gadotti	 
	 	Name: 	Alessandro Gadotti	 
	 	Title:	CEO	 

 

	Aditxt, Inc.	 
	 	 	 	 
	By:	/s/ Amro Albanna	 
	 	Name: 	Amro Albanna	 
	 	Title:	CEO	 

 

 

-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]